Oregon CPOM Doctrine: Regulating Corporate Control in Healthcare
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study,involving over 17,600 participants,showed a statistically notable,though relatively small,increase in thes events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: Key Details
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. Participants were randomly assigned to recieve either 2.4 mg of semaglutide weekly or a placebo, along with their standard cardiovascular care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. Over an average of 3.4 years, the semaglutide group experienced a 15% increased risk of these events.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.9% | 1.34 (1.07-1.67) |
| Nonfatal Myocardial Infarction | 2.6% | 2.2% | 1.18 (0.94-1.48) |
| Nonfatal Stroke | 3.7% | 3.3% | 1.11 (0.87-1.42) |
| Unstable Angina Requiring Hospitalization | 1.2% | 1.0% | 1.20 (0.84-1.71) |
Data from the SELECT trial, New England Journal of Medicine, Ahead of Print.
What Does This Mean? Beyond the Headlines
The increased risk, while statistically significant, is significant to contextualize. The absolute risk difference was relatively small – approximately 1.3% over the study period.However, for individuals already vulnerable due to existing heart disease, even a small increase in risk is concerning. This doesn’t necessarily mean semaglutide is inherently hazardous for everyone; rather, it highlights the need for careful patient selection and monitoring.